Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
申请人:EPIZYME, INC.
公开号:US10266526B2
公开(公告)日:2019-04-23
The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
Schroeder et al., Chemische Berichte, 1965, vol. 98, p. 2556
作者:Schroeder et al.
DOI:——
日期:——
SMYD Inhibitors
申请人:EPIZYME, INC.
公开号:US20170355695A1
公开(公告)日:2017-12-14
The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
SMYD INHIBITORS
申请人:EPIZYME, INC.
公开号:US20190322660A1
公开(公告)日:2019-10-24
The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmacentically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
유기발광 화합물 및 이를 포함하는 유기전계발광소자
申请人:Samsung Display Co., Ltd. 삼성디스플레이 주식회사(120120164552) Corp. No ▼ 134511-0187812
公开号:KR20150043571A
公开(公告)日:2015-04-23
본 발명은 하기 [화학식 1-1] 내지 [화학식 1-2]로 표시되는 유기발광 화합물에 관한 것으로서, 이를 채용한 유기전계발광소자느 발광 효율이 우수하면서도 동시에 저전압 구동이 가능하여 향상된 전력효율과 장수명 특성을 갖는다. [화학식 1-1] [화학식 1-2]